|Convertible Note Agreement | AC Immune SA, 11 December 2018||21/23|
Prof. Dr. Andrea Pfeifer
Innovation Park Building B
Prof. Dr. Andrea Pfeifer,
We refer to the convertible note agreement
dated 11 December 2018 (the “Agreement”) between AC Immune SA as borrower and our company Eli Lilly
and Company as lender.
terms used in this Conversion Notice but not otherwise defined herein shall have the meaning ascribed to them in the Agreement.
full knowledge of the Borrower’s articles of association, we hereby:
the conversion of the Loan and the interest due, in accordance with Article 5 of the
Agreement for an amount corresponding to our claim against the Borrower as per [date]
under the Agreement, i.e., USD [amount], into [number] common shares (the “Relevant
Shares”) in the Borrower; and|
the Borrower to provide us with the Borrower’s commercial register excerpt giving
evidence of the issuance of Relevant Shares.|
|Eli Lilly and Company|